Surgery Partners financials
$14.41−1.91%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $848.9M | $810.9M | $885.0M | $821.5M | $826.2M | $776.0M | $864.4M | $770.4M | $762.1M | $717.4M | $735.4M | $674.1M |
| Gross profit | $848.9M | $810.9M | $885.0M | $821.5M | $826.2M | $776.0M | $864.4M | $770.4M | $762.1M | $717.4M | $735.4M | $674.1M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | $98.1M | $66.0M | $113.7M | $117.4M | $103.2M | $62.7M | $133.9M | $70.4M | $90.8M | $72.8M | $114.7M | $83.7M |
| Net income | -$15.0M | -$35.9M | -$15.0M | -$22.7M | -$2.5M | -$37.7M | -$108.5M | -$31.7M | -$15.5M | -$12.4M | -$1.0M | -$4.9M |
| Net margin | −1.8% | −4.4% | −1.7% | −2.8% | −0.3% | −4.9% | −12.6% | −4.1% | −2.0% | −1.7% | −0.1% | −0.7% |
| Diluted EPS | $-0.12 | $-0.28 | $-0.12 | $-0.18 | $-0.02 | $-0.30 | $-0.86 | $-0.25 | $-0.12 | $-0.10 | $-0.01 | $-0.04 |
| EBITDA | $155.8M | $122.6M | $193.4M | $174.6M | $161.6M | $125.9M | $206.9M | $150.5M | $145.4M | $122.1M | $141.6M | $129.0M |
| Operating cash flow | $59.3M | $11.7M | $103.4M | $83.6M | $81.3M | $6.0M | $111.4M | $65.2M | $82.8M | $40.7M | $62.6M | $104.6M |
| Free cash flow | $37.5M | -$4.3M | $90.6M | $63.8M | $57.9M | -$16.7M | $89.1M | $45.0M | $55.9M | $19.7M | $42.8M | $85.7M |
| Diluted shares | 128.8M | 128.4M | 128.0M | 127.2M | 127.0M | 126.6M | 126.2M | 126.2M | 126.1M | 126.0M | 124.1M | 125.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $216.7M | $182.3M | $239.9M | $203.4M | $250.1M | $229.3M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $3.75B | $3.71B | $3.70B | $3.56B | $3.58B | $3.55B |
| Total assets | $8.05B | $8.04B | $8.12B | $7.95B | $7.95B | $7.95B |
| Total liabilities | $4.58B | $4.56B | $4.59B | $4.39B | $4.38B | $4.36B |
| Shareholders' equity | $3.10B | $3.10B | $3.13B | $3.14B | $3.16B | $3.16B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology